Quality Control of MHC Class I Restricted Antigen Processing
MHC I 类限制性抗原加工的质量控制
基本信息
- 批准号:9175668
- 负责人:
- 金额:$ 45.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-15 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntigen-Presenting CellsAntigensAutoimmunityBindingBiochemicalBiologicalCD8B1 geneCellsComplexCross PresentationCytosolDendritic CellsDisulfidesERp57Endoplasmic ReticulumEnsureEnzymesGenerationsGlucoseGlycoproteinsGoalsHistocompatibility Antigens Class IHomologous GeneI-antigenImmuneIn VitroInfectionLeadLectinLinkMHC Class I GenesMalignant NeoplasmsMediatingMolecular ChaperonesOxidoreductasePathway interactionsPeptidesPhagosomesPlayPolysaccharidesProcessProtein FragmentProteinsQuality ControlReactionRoleSignal TransductionStructureSulfhydryl CompoundsT cell responseT-LymphocyteTestingTransferaseTranslatingVirusantigen processingantigenic peptide transportercalreticulindimerfightingflexibilitykillingsmulticatalytic endopeptidase complexneoplastic cellpathogenpeptide Iprotein complextapasintumor
项目摘要
Project Summary
MHC class I-restricted antigen processing is essential for making CD8+ T cell responses. It must function
correctly for effective immune recognition of pathogens, and aberrations can lead to autoimmunity. The
overall aim of this proposal is to understand the quality control processes regulating MHC class I-
restricted antigen processing of conventional antigens, translated in the cytosol, and of exogenous
antigens internalized by cross-presenting cells. The latter process is particularly poorly characterized, yet
it is essential for priming CD8+ T cell responses. We wish to understand how these two different
processing mechanisms drive the assembly of essentially the same pool of MHC-I peptide complexes. A
critical quality control process in the endoplasmic reticulum (ER) that remains ill understood is the action
of the enzyme UDP-glucose glycoprotein transferase (UGT1), which produces the correct
monoglucosylated glycan structure that allows MHC-I molecules to maintain an interaction with the
Peptide Loading Complex (PLC) via the lectin chaperone calreticulin, facilitating tapasin-mediated
peptide exchange. This promotes the expression by the cell of complexes of MHC-I with peptides of high
affinity. We will test the hypothesis that structural flexibility in the MHC-I peptide binding domain serves
as a recognition signal for UGT1. A second component, which is found in both the ER and the endocytic
pathway, is the tapasin homologue TAPBPR. In vitro, TAPBPR can induce peptide exchange by MHC-I
molecules outside of the PLC, and it has also been shown to interact with UGT1. A second major goal is
to determine whether TAPBPR mediates peptide exchange by MHC class I molecules in intact cells,
whether this can occur both in the ER and the phagosomes of cross-presenting cells, and whether in
either of these intracellular compartments the simultaneous interaction of TAPBPR with UGT1 focuses
the enzymatic activity of UGT1 onto MHC-I molecules associated with low affinity peptides, facilitating
their exchange for optimal peptides. The final goal is to determine how cross-presented intact antigens
encounter proteasomes, which are essential for both conventional MHC-I antigen processing and cross-
presentation. We have evidence that this interaction occurs proximal to, and probably within,
phagosomes of cross-presenting cells. The mechanisms that regulate this interaction at both the cell
biological and biochemical level will be investigated.
项目摘要
MHC-I类限制性抗原的处理对于产生CD8+T细胞反应是必不可少的。它必须发挥作用
正确用于有效识别病原体的免疫,而异常可导致自身免疫。这个
这项建议的总体目标是了解管理MHC I类的质量控制程序-
在胞浆中翻译的常规抗原和外源抗原的限制性抗原加工
由交叉提呈细胞内化的抗原。后一种过程的特点尤其糟糕,但
它是启动CD8+T细胞反应的关键。我们希望了解这两个不同之处
加工机制驱动基本上相同的MHC-I多肽复合体的组装。一个
内质网(ER)中的关键质量控制过程仍然不清楚的是
UDP-葡萄糖糖蛋白转移酶(UGT1)的活性,它能产生正确的
单糖化的多糖结构,允许MHC-I分子与MHC-I保持相互作用
通过凝集素伴侣钙网织蛋白的多肽负载复合体(PLC),促进Tapasin介导
多肽交换。这促进了MHC-I与高密度脂蛋白多肽的复合体的细胞表达
亲和力。我们将检验这样一个假设,即MHC-I肽结合域的结构灵活性是
作为UGT1的识别信号。第二种成分,在内质网和内质网中都有
途径,是TAPASIN的同源物TAPBPR。在体外,TAPBPR可通过MHC-I诱导多肽交换
在PLC之外的分子,它也被证明与UGT1相互作用。第二个主要目标是
为了确定TAPBPR是否通过MHC I类分子在完整细胞中介导肽交换,
这是否可以同时发生在内质网和交叉呈递细胞的吞噬小体中,以及是否在
TAPBPR与UGT1焦点的同时相互作用
UGT1对与低亲和力多肽相关的MHC-I分子的酶活性
它们用来交换最佳的多肽。最终目标是确定交叉呈现完整抗原的方式。
遇到蛋白酶体,它对传统的MHC-I抗原处理和交叉反应都是必不可少的
演示文稿。我们有证据表明,这种相互作用发生在附近,而且可能在内部,
交叉呈递细胞的吞噬小体。在两个细胞中调节这种相互作用的机制
将对生物和生化水平进行调查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER CRESSWELL其他文献
PETER CRESSWELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER CRESSWELL', 18)}}的其他基金
SARS-CoV-2 infection and MHC class I function in bats
蝙蝠中的 SARS-CoV-2 感染和 MHC I 类功能
- 批准号:
10549369 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
SARS-CoV-2 infection and MHC class I function in bats
蝙蝠中的 SARS-CoV-2 感染和 MHC I 类功能
- 批准号:
10451136 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Mechanisms of antigen cross-presentation by MHC class I molecules
MHC I 类分子的抗原交叉呈递机制
- 批准号:
10413224 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Mechanisms of antigen cross-presentation by MHC class I molecules
MHC I 类分子的抗原交叉呈递机制
- 批准号:
10276760 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Mechanisms of antigen cross-presentation by MHC class I molecules
MHC I 类分子的抗原交叉呈递机制
- 批准号:
10624950 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
The role of GILT in the generation of reactive oxygen species
GILT 在活性氧生成中的作用
- 批准号:
9091406 - 财政年份:2015
- 资助金额:
$ 45.83万 - 项目类别:
The role of GILT in the generation of reactive oxygen species
GILT 在活性氧生成中的作用
- 批准号:
8951439 - 财政年份:2015
- 资助金额:
$ 45.83万 - 项目类别:
Quality Control of MHC Class I Restricted Antigen Processing
MHC I 类限制性抗原加工的质量控制
- 批准号:
8662182 - 财政年份:2012
- 资助金额:
$ 45.83万 - 项目类别:
Quality Control of MHC Class I Restricted Antigen Processing
MHC I 类限制性抗原加工的质量控制
- 批准号:
9925726 - 财政年份:2012
- 资助金额:
$ 45.83万 - 项目类别:
Quality Control of MHC Class I Restricted Antigen Processing
MHC I 类限制性抗原加工的质量控制
- 批准号:
9275343 - 财政年份:2012
- 资助金额:
$ 45.83万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




